Healthcare Industry News: neuromodulation
News Release - December 2, 2009
Medtronic Names Michael J. Coyle as Executive Vice President and Group President of Cardiology BusinessesMINNEAPOLIS--(HSMN NewsFeed)--Medtronic, Inc. (NYSE:MDT ), today announced the appointment of Michael J. Coyle as executive vice president and group president of its Cardiology businesses. Coyle will lead all aspects of the group, which includes the company’s Cardiac Rhythm Disease Management (CRDM), CardioVascular and Physio-Control businesses. He will be a member of the Executive Committee and report to Chairman and CEO Bill Hawkins.
Reporting to Coyle will be Pat Mackin, senior vice president and president, CRDM; Scott Ward, senior vice president and president, CardioVascular; and Brian Webster, president, Physio-Control.
“Mike brings to Medtronic more than 25 years of industry experience and proven technical leadership, both complementing and strengthening the exceptional management teams within our cardiac businesses,” said Hawkins. “His deep experience in medical device therapy will enable us to build on the emerging synergies within these businesses and to accelerate their market leading performance.”
Prior to joining Medtronic, Coyle held a number of leadership positions in the medical technology industry, most recently leveraging his broad healthcare industry knowledge and expertise to advise and provide leadership consulting services to private equity, venture capital and medical device firms across the country. He served as president of St. Jude Medical’s Cardiac Rhythm Management division from 2001 to 2007, where he led that company’s global pacemaker, implantable cardioverter defibrillator and cardiac resynchronization therapy businesses, and from 1997 to 2001, served as president of St. Jude’s Daig Catheter division. Prior to St. Jude, he held various leadership positions at Eli Lilly & Company.
Coyle received his master’s degree in business administration specializing in finance and marketing from the Wharton School of Business and also holds a chemical engineering degree from Case Western Reserve University.
Earlier this year, Medtronic announced it was consolidating its businesses into two operating groups, which combined its Cardiac Rhythm Disease Management CardioVascular and Physio-Control businesses; and the other which combined its Spinal and Biologics, neuromodulation, Diabetes, and Surgical Technologies businesses. The move was designed to leverage technologies, customers and synergies across its businesses and to further advance its goal of One Medtronic - an integrated company focused on the treatment of chronic disease.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 24, 2009. Actual results may differ materially from anticipated results.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMedtronic Expands ENT Portfolio with FDA Clearance of NIM Vital(TM) Next Generation Intraoperative Nerve Monitoring System and Acquisiton of Ai Biomed Corp.
Medtronic Launches Head-to-Head TAVR Study Comparing the Evolut(TM) TAVR Platform Against the Edwards SAPIEN Valve in Small Annulus Patients
Medtronic Announces First Patient Implanted in ELITE Study of InterStim(TM) Micro